Blog

Every article in one place — research, news & community insights. RSS feed →

News · May 20, 2026

The GLP-1 Pipeline in 2026: Beyond Semaglutide and Tirzepatide

Dual and triple incretin agonists, oral formulations, and muscle-preservation combinations are reshaping the metabolic landscape. A neutral look at what's approved, what's in trials, and what's still hype.

Insight · May 15, 2026

What People Actually Report About BPC-157 (Synthesized)

A paraphrased synthesis of recurring themes in public BPC-157 discussion — what people say they use it for, the patterns they describe, and where those reports diverge from the evidence. Anecdotal, never copied verbatim.